BioTissue to Present Research Into the Application of Cryopreserved Amniotic Membrane (CAM) at ASCRS
Ophthalmologists at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Boston will be sharing research that offers new insights into the application of Cryopreserved Amniotic Membrane (CAM). Among these advancements is the utilization of BioTissue’s Prokera Slim in optimizing the ocular surface across many differing clinical scenarios.
BioTissue uses cryopreserved human birth tissue products for regenerative healing for chronic wounds, musculoskeletal conditions, and ocular surface diseases and disorders.
“These four studies may reshape the landscape of ocular surface space,” BioTissue CEO Ted Davis said in a company news release. “The advancements highlighted in these studies not only reinforce our dedication to innovative solutions, but also emphasize the positive impact of CAM on patients’ lives.”
The following papers and posters will be featured at ASCRS:
- Effect of Cryopreserved Amniotic Membrane on Optimizing the Ocular Surface Prior to Cataract Surgery
Jeff Wongs, MD
The study evaluates the effectiveness of CAM, in particular Prokera® Slim, in improving the ocular surface and enhancing the accuracy of biometry readings before cataract surgery for better post-operative refractive outcomes. Preliminary findings from 32 eyes demonstrated significant improvements in SPEED scores, NEI staining scores, and BCVA after AM treatment. Moreover, 97% of eyes achieved 20/20 BCVA one-month post-cataract surgery, with 78% attaining emmetropia, suggesting that CAM placement optimizes the ocular surface and contributes to post-surgical refractive success.
Brett P. Bielory, MD
This analysis reports the outcomes of managing a severe limbal scleral defect post-pterygium surgery using self-retained CAM, specifically Prokera®. In a 57-year-old male with recurrent pterygium, self-retained AM application resulted in increased scleral thickness, complete conjunctival epithelialization, and improved visual acuity without signs of inflammation, demonstrating the effectiveness of in-office AM management for ocular surface recovery in such cases.
Ravi Krishnan, MD
This study evaluates the retrobulbar injection of micronized AM for managing intractable ocular pain. Four patients with recalcitrant ocular pain, contemplating enucleation of evisceration, showed a significant reduction in pain scores after the injection, with sustained relief and improved visual acuity observed during an average follow-up of 46-weeks, suggesting the potential utility of this approach in providing symptomatic improvement without complications.
Kurt Hanebrink, MD, Ankur A. Parikh, MD, and Amar P. Shah, MD, MBA
This study assesses intraocular lens (IOL) selection and post-cataract surgery visual outcomes in patients with epithelial basement membrane dystrophy and/or Salzmann nodular degeneration undergoing staged phototherapeutic keratectomy (PTK)/cryopreserved amniotic membrane (CAM) + cataract surgery (CE/IOL) compared to staged PTK + CE/IOL.
Paper presentations will take place at Boston Convention and Exhibition Center. Dr. Parikh is scheduled to present his paper on Saturday, April 6 at 2:20 p.m. at meeting level 2, room 260, and Dr. Wongs will present his paper on Sunday, April 7 at 4:35 p.m. at meeting level 2, room 259B. Posters will be available for viewing on-demand in the Education Hub at the convention center during the meeting and available for viewing on the ASCRS website post-meeting.